Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30920916 | 0.84 | GRM5 (0.52) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL10223421 | 0.84 | GRM5 (0.52) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL29090196 | 0.82 | GRM5 (0.44) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL29090207 | 0.82 | GRM5 (0.44) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| Methyl Alcohol SCHEMBL28902013 | 0.81 | GRM5 (0.67) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL31257818 | 0.81 | GRM5 (0.49) | GRM5KCNH2CYP1A2L3MBTL1ALDH1A1 | |
| SCHEMBL11269556 | 0.78 | ASIC3 (0.44) | GRM5CYP1A2L3MBTL1ALDH1A1PKM | |
| SCHEMBL352291 | 0.76 | GRM5 (0.65) | GRM5KCNH2CYP1A2 | |
| SCHEMBL31179728 | 0.75 | GRM5 (0.44) | GRM5KCNH2CYP1A2 | |
| SCHEMBL5545972 | 0.74 | TTBK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | GRM5 2824/4885KCNH2 3818/4885CYP1A2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.